NCT05025735 2021-10-19Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast CancerSaint Luke's Health SystemPhase 2 Unknown25 enrolled